News and Trends 14 Nov 2019
Cellectis’ Off-the-Shelf CAR T-Cell Therapy Shows Solid Tumor Potential
An off-the-shelf, gene edited CAR T-cell therapy, developed by the French biotech Cellectis, could be used to tackle solid tumors, which have so far been beyond the reach of other CAR T-cell therapies. The approved CAR T-cell therapies Kymriah and Yescarta contain genetically modified immune T-cells that can fight certain types of blood cancer. However, […]
